Results 91 to 100 of about 51,855 (253)
Diagnosis of Portal Hypertension: Advancing Towards Non‐Invasive Solutions
Portal Hypertension &Cirrhosis, EarlyView.This review systematically summarizes a full spectrum of non‐invasive diagnostic approaches for portal hypertension (PH), including imaging modalities, elastography, serum biomarkers, composite scoring systems and endoscopic ultrasound‐guided portal pressure gradient (EUS‐PPG), and analyzes their performance across different liver disease etiologies ...
Lijia Yin, Huikuan Chu, Ling Yang
wiley +1 more source
Ashwagandha: Is It Safe? Part 2: A Preclinical Evidence Review
Phytotherapy Research, EarlyView.ABSTRACT The preclinical evidence for the safety of ashwagandha (Withania somnifera (L.) Dunal, AS) is reviewed, and its preparations (extracts) and constituents, from the general toxicity in animal models to in vitro and cell culture studies, which may elucidate mechanisms of action and explain clinical case reports.
Elizabeth M. Williamson, Thomas Brendler
wiley +1 more source
Staging concept for aging management: Definition, mechanism, and coping strategies
VIEW, EarlyView.We divided the overall aging stage into “pre‐aging”, “aging compensation”, and “aging disability”. For each stage, we delineate the clinical presentations, biological phenomena, theoretical underpinnings, and key management priorities. Abstract Aging, as a gradual and largely irreversible biological process, characterized by declining organismal ...
Zhonghan Wang +6 more
wiley +1 more source
Allergy, EarlyView.ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter +20 more
wiley +1 more source
First Latin American consensus on the treatment and prophylaxis of hepatic encephalopathy
Annals of HepatologyIntroduction and Objectives: Hepatic encephalopathy (HE) is a frequent and severe complication of cirrhosis, leading to rapid deterioration and increased mortality.
Fátima Higuera-de-la-Tijera +14 more
doaj +1 more source
Artificial Organs, EarlyView.ALSS short inter‐treatment interval treatment (patients received two ALSS treatments within 48 h) correlates with improved liver function and 90‐day transplant‐free survival of HBV‐ACLF. This result provides a certain theoretical basis for the timing and time interval of ALSS for HBV‐ACLF, enriches the models and contents of ALSS treatment for HBV‐ACLF,
Jingjie Fu +4 more
wiley +1 more source
Artificial Organs, EarlyView.Extracorporeal albumin dialysis (OPAL) effectively reduces bilirubin and improves other laboratory markers in posthepatectomy liver failure, particularly in secondary forms. It may serve as a bridging therapy to support hepatic recovery in critically ill patients, although prospective studies are needed to confirm its impact on survival.
Dorian Marckmann +16 more
wiley +1 more source
Clinical Burden of Symptomatic HEV‐3 Infection in Southern Spain
Alimentary Pharmacology &Therapeutics, EarlyView.Clinical burden of symptomatic HEV‐3 infection in southern Spain. Between 2022 and 2025, 1124 patients with acute hepatitis, defined as ALT ≥ 3 times the upper limit of normal and negative screening for HAV, HBV, HCV, EBV and CMV, were evaluated in Andalusia.
María Casares‐Jimenez +14 more
wiley +1 more source
Evaluation on life quality of healed patients with hepatic encephalopathy and nursing care of them
Huli yanjiu, 2004 Objective: to evaluate the life quality of healed patients with hepatic encephalopathy, to provide a basis for nursing care of them. Method: a total of 80 healed cases with hepatic encephalopathy and another 100 cases of healthy individuals were selected
赖敏贞, 文若兰, 廖少玲
doaj
Alimentary Pharmacology &Therapeutics, EarlyView.RESTORE is a prospective, double‐blind, placebo‐controlled, crossover trial evaluating Lemborexant in cirrhosis at Cipto Mangunkusumo National Referral Hospital. Both 5 and 10 mg doses reduced PSQI by week 2, with sustained benefits post‐crossover. The 5 mg group improved Stroop Test performance, whereas the 10 mg group had prolonged reaction time ...
Rino Alvani Gani +7 more
wiley +1 more source